Annexon (ANNX) vs Verastem (VSTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Annexon (ANNX) has outperformed Verastem (VSTM) over the past year, gaining 27.0% versus a loss of 9.3%. Over five years, VSTM leads with a -75.5% price change compared with -81.8% for ANNX. Annexon is the larger company by market cap ($758.3 million vs $734.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | VSTM |
|---|---|---|
| Share price | $4.00 | $8.11 |
| Market cap | $758.32M | $734.47M |
| 1-day change | -0.25% | -1.88% |
| YTD return | -20.32% | +5.05% |
| 1-year return | +26.98% | -9.28% |
| 5-year return | -81.82% | -75.51% |
| EPS (TTM) | $-1.13 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $10.82 |
| 52-week low | $2.54 | $3.43 |
| Distance from 52-week high | -44.29% | -25.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +84.96% |
| Average volume | 3.11M | 2.25M |
| Shares outstanding | 189.58M | 90.56M |
| Employees | 92 | 102 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed VSTM by 36.3 percentage points over the past year.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About Verastem
VSTM stock →Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Healthcare · Biotechnology · 102 employees
ANNX vs VSTM FAQ
Which is bigger, Annexon or Verastem?
Annexon (ANNX) is larger, with a market capitalization of $758.32M compared with $734.47M for Verastem (VSTM).
Which stock has performed better over the past year, ANNX or VSTM?
ANNX returned +26.98% over the past 12 months, compared with -9.28% for VSTM (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Verastem in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.